Serum Type I Interferon Score predicts clinically meaningful disease progression in limited cutaneous Systemic Sclerosis

IF 11.4 1区医学 Q1 RHEUMATOLOGY

Arthritis & Rheumatology Pub Date : 2025-01-29 DOI:10.1002/art.43120

Stefano Di Donato, Rebecca Ross, Ranjitha Karanth, Vishal Kakkar, Enrico De Lorenzis, Lesley-Anne Bissell, Kristina Clark, Philip Yee, Christopher P. Denton, Francesco Del Galdo

引用次数: 0

Abstract

To assess the value of serum Type I Interferon (IFN) score in predicting clinically meaningful progression in limited cutaneous systemic sclerosis (lcSSc) using a novel composite endpoint adopted from the MINIMISE clinical trial.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Arthritis & Rheumatology RHEUMATOLOGY-

CiteScore

20.90

自引率

3.00%

发文量

371

期刊介绍： Arthritis & Rheumatology is the official journal of the American College of Rheumatology and focuses on the natural history, pathophysiology, treatment, and outcome of rheumatic diseases. It is a peer-reviewed publication that aims to provide the highest quality basic and clinical research in this field. The journal covers a wide range of investigative areas and also includes review articles, editorials, and educational material for researchers and clinicians. Being recognized as a leading research journal in rheumatology, Arthritis & Rheumatology serves the global community of rheumatology investigators and clinicians.